Leon Aarons

Leon Aarons's AcademicInfluence.com Rankings

Leon Aarons

Chemistry

#5070

World Rank

#6184

Historical Rank

chemistry Degrees

Download Badge

Chemistry

Why Is Leon Aarons Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Leon Aarons is an Australian chemist who researches and teaches in the areas of pharmacodynamics and pharmacokinetics. He lives in the United Kingdom and from 1976 has been a professor of pharmacometrics at the University of Manchester. In the interest of promoting the effective development of drugs, the main focus of his work is optimizing pharmacological models, the design of clinical studies, and data analysis and interpretation in the field of population pharmacokinetics. From 1985 to 2010 Aarons was an editor emeritus of the Journal of Pharmacokinetics and Pharmacodynamics and is a former executive editor of the British Journal of Clinical Pharmacology.

(See a Problem?)

Leon Aarons's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

PBPK models for the prediction of in vivo performance of oral dosage forms. (2014) (257)
Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data (2015) (203)
Population pharmacokinetics: theory and practice. (1991) (190)
Molecular Analysis of the Subgingival Microbiota in Health and Disease (2006) (170)
Population pharmacokinetics. (1992) (160)
Why Has Model‐Informed Precision Dosing Not Yet Become Common Clinical Reality? Lessons From the Past and a Roadmap for the Future (2017) (138)
The Use of Population Pharmacokinetics in Drug Development (1996) (136)
Mefloquine Pharmacokinetic-Pharmacodynamic Models: Implications for Dosing and Resistance (2000) (134)
Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection (2002) (129)
Lumping of Whole-Body Physiologically Based Pharmacokinetic Models (1998) (128)
Enoxacin‐warfarin interaction: Pharmacokinetic and stereochemical aspects (1987) (125)
Critique of the Two-Fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-Drug Interactions (2011) (108)
Role of modelling and simulation in Phase I drug development. (2001) (102)
Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo. (2014) (101)
Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study (2010) (98)
Population pharmacokinetics of mefloquine in patients with acute falciparum malaria (1999) (95)
Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. (2009) (92)
Software for Population Pharmacokinetics and Pharmacodynamics (1999) (91)
The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. (2012) (85)
Mixed Effects Models for the Population Approach: Models, Tasks, Methods, and Tools (2015) (84)
Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed. (2005) (83)
Quantitative Structure-Pharmacokinetics Relationships: I. Development of a Whole-Body Physiologically Based Model to Characterize Changes in Pharmacokinetics Across a Homologous Series of Barbiturates in the Rat (1997) (75)
Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. (2005) (72)
Dose-response study with ibuprofen in rheumatoid arthritis: clinical and pharmacokinetic findings. (1983) (70)
Use of Nonlinear Mixed-Effects Analysis for Improved Precision of Early Pharmacodynamic Measures in Tuberculosis Treatment (2006) (68)
Quantitative characterization of therapeutic index: Application of mixed‐effects modeling to evaluate oxybutynin dose–efficacy and dose–side effect relationships (1999) (68)
Proper lumping in systems biology models. (2009) (58)
IMI – Oral biopharmaceutics tools project – Evaluation of bottom‐up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results (2017) (56)
Optimal Design for Multivariate Response Pharmacokinetic Models (2006) (55)
Optimal design of pharmacokinetic studies. (2010) (53)
Comparison of in‐vivo and in‐silico methods used for prediction of tissue: plasma partition coefficients in rat (2012) (52)
Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach (2015) (52)
Identification of the Effect of Multiple Polymorphisms on the Pharmacokinetics of Simvastatin and Simvastatin Acid Using a Population‐Modeling Approach (2014) (51)
Population pharmacokinetics of tobramycin. (1989) (50)
Corticosteroid‐binding globulin regulates cortisol pharmacokinetics (2011) (49)
A pharmacokinetic simulation model for ivabradine in healthy volunteers. (2000) (49)
A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models (2007) (48)
Population pharmacokinetics of artemether and dihydroartemisinin following single intramuscular dosing of artemether in African children with severe falciparum malaria. (2003) (48)
Modeling and Simulation for Clinical Trial Design Involving a Categorical Response: A Phase II Case Study with Naratriptan (2001) (44)
Validation of assay methodology used in pharmacokinetic studies. (1987) (42)
Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies (2004) (40)
IMI – Oral biopharmaceutics tools project – Evaluation of bottom‐up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes (2017) (39)
Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM (2007) (39)
Optimal Design of a Population Pharmacodynamic Experiment for Ivabradine (2004) (38)
A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979) (2003) (38)
Markov Chain Monte Carlo Techniques for Studying Interoccasion and Intersubject Variability: Application to Pharmacokinetic Data (1997) (37)
Pharmacokinetics of lidocaine and its deethylated metabolite: Dose and time dependency studies in man (1982) (37)
Aspirin binding and the effect of albumin on spontaneous and enzyme‐catalysed hydrolysis (1980) (37)
Estimation of area under the curve for drugs subject to enterohepatic cycling (1985) (36)
An Identifiability Analysis of a Parent–Metabolite Pharmacokinetic Model for Ivabradine (2001) (35)
Satellite peaks in the high energy photoelectron spectra of some small first row molecules (1973) (35)
IMI – oral biopharmaceutics tools project – evaluation of bottom‐up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds (2017) (35)
Interpretation of area under the curve measurements for drugs subject to enterohepatic cycling. (1985) (35)
What do we mean by identifiability in mixed effects models? (2016) (34)
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers (2009) (34)
Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin (2010) (34)
The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experiments (2005) (34)
How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach (2008) (33)
Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments (2006) (33)
Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers. (2000) (32)
Pharmacokinetics of a Single Bolus of Propofol in Chinese Children of Different Ages (2006) (32)
Population pharmacokinetics of ondansetron: a covariate analysis. (1998) (31)
Simultaneous assay of fluoroquinolones and theophylline in plasma by high-performance liquid chromatography. (1993) (31)
Diazepam Pharamacokinetics from Preclinical to Phase I Using a Bayesian Population Physiologically Based Pharmacokinetic Model with Informative Prior Distributions in Winbugs (2006) (31)
Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients. (2005) (31)
Route of Administration and Sex Differences in the Pharmacokinetics of Aspirin, Administered as Its Lysine Salt (1989) (31)
Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions (2015) (30)
Quantitative Structure–Pharmacokinetics Relationships: II. A Mechanistically Based Model to Evaluate the Relationship Between Tissue Distribution Parameters and Compound Lipophilicity (1998) (30)
Physiologically Based Pharmacokinetic Modeling of a Homologous Series of Barbiturates in the Rat: A Sensitivity Analysis (1997) (30)
Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. (2011) (30)
The estimation of population pharmacokinetic parameters using an EM algorithm. (1993) (29)
Population pharmacokinetic analysis of ropivacaine and its metabolite 2',6'-pipecoloxylidide from pooled data in neonates, infants, and children. (2011) (29)
Application of optimal design methodologies in clinical pharmacology experiments (2009) (29)
Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model. (2015) (29)
A physiologically based pharmacokinetic model for Valproic acid in adults and children. (2014) (29)
Population pharmacokinetics and pharmacodynamics of warfarin in healthy young adults (1993) (29)
Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies (2011) (29)
Drug–drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes (2008) (29)
"The Bayesian approach to population pharmacokinetic/pharmacodynamic modeling". In: Case Studies in Bayesian Statistics (Vol IV), Lecture Notes in Statistics (1999) (28)
A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979). (2003) (28)
Incorporating physiological and biochemical mechanisms into pharmacokinetic-pharmacodynamic models: a conceptual framework. (2009) (28)
Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin. (1990) (28)
Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models (2016) (27)
Problems associated with analysis and interpretation of small molecule/macromolecule binding data (1978) (27)
Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 1: methotrexate (2014) (27)
Rate and Extent of Absorption of Clonidine from a Transdermal Therapeutic System (1989) (26)
Determination of an Optimal Dosage Regimen Using a Bayesian Decision Analysis of Efficacy and Adverse Effect Data (2002) (26)
Satellite phenomena in the high energy photoelectron spectra of tetramethyl-p-phenylenediamine (TMPD), tetracyanoquinodimethane (TCNQ), and their derivatives. Experimental and theoretical study (1973) (26)
Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. (2006) (26)
Interpretation of high energy photoelectron spectra satellite peaks by semi-empirical molecular orbital calculations (1972) (25)
Intravenous Phenytoin Loading in Patients after Neurosurgery and in Status Epilepticus (1988) (25)
Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979) (2004) (24)
Efficiency of Drug Targeting: Steady-State Considerations Using a Three-Compartment Model (1989) (24)
Population pharmacokinetics and optimal design of paediatric studies for famciclovir. (2009) (24)
Plasma and synovial fluid kinetics of flurbiprofen in rheumatoid arthritis. (1986) (24)
Development of a Novel Simplified PBPK Absorption Model to Explain the Higher Relative Bioavailability of the OROS® Formulation of Oxybutynin (2016) (23)
Translating Human Effective Jejunal Intestinal Permeability to Surface-Dependent Intrinsic Permeability: a Pragmatic Method for a More Mechanistic Prediction of Regional Oral Drug Absorption (2015) (23)
Population pharmacokinetics of free carbamazepine in adult Omani epileptic patients (2001) (23)
A Bayesian Method Based on Clotting Factor Activity for the Prediction of Maintenance Warfarin Dosage Regimens (2003) (23)
Pharmacokinetic and pharmacodynamic modelling in drug development. (1999) (22)
A rapid method for the simultaneous determination of the major metabolites of sulphasalazine in plasma. (1983) (22)
Sample Size Calculations Based on Generalized Estimating Equations for Population Pharmacokinetic Experiments (2006) (22)
Optimal Design for Multiresponse Pharmacokinetic–Pharmacodynamic Models – Dealing with Unbalanced Designs (2007) (21)
The Pharmacokinetics of Saquinavir: A Markov Chain Monte Carlo Population Analysis (1998) (21)
Empirical and Semi-Mechanistic Modelling of Double-Peaked Pharmacokinetic Profile Phenomenon Due to Gastric Emptying (2014) (21)
Optimal sampling strategies for early pharmacodynamic measures in tuberculosis. (2006) (21)
Electron spin resonance studies of thiocarbonyl anion radicals (1972) (20)
Uncertainty Analysis in Pharmacokinetics and Pharmacodynamics: Application to Naratriptan (2005) (20)
A method for robust model order reduction in pharmacokinetics (2009) (20)
Theoretical study of the geometry of PH3, PF3 and their ground ionic states (1973) (20)
The Use of ROC Analysis for the Qualitative Prediction of Human Oral Bioavailability from Animal Data (2013) (20)
Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate (2014) (19)
How can we do pharmacokinetic studies in the tropics? (2001) (19)
Inter-relationship among individual vitamin K-dependent clotting factors at different levels of anticoagulation. (1987) (19)
Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study. (2005) (19)
The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans (1999) (19)
New strategies in drug development and clinical evaluation: the population approach (1993) (19)
Sample Size/Power Calculations for Population Pharmacodynamic Experiments Involving Repeated-Count Measurements (2009) (19)
A chronic dose-ranging study of the pharmacokinetics of phenylbutazone in rheumatoid arthritic patients. (1981) (18)
Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. (2008) (18)
The design and analysis of parallel experiments to produce structurally identifiable models (2013) (18)
The binding of ibuprofen to plasma proteins (2004) (18)
Anti-inflammatory (ibuprofen) drug therapy in rheumatoid arthritis--rate of response and lack of time dependency of plasma pharmacokinetics. (1983) (18)
IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies. (2020) (17)
Modelling and Simulation in the Development and use of Anti-Cancer Agents: An Underused Tool? (2004) (17)
A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat (1991) (17)
Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations (2015) (17)
An in vitro study of drug displacement interactions: warfarin‐salicylate and warfarin‐phenylbutazone (1979) (17)
Population Fisher information matrix and optimal design of discrete data responses in population pharmacodynamic experiments (2009) (17)
Effect of experimental design on assay calibration (1981) (17)
Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics (2015) (17)
Use of Koopmans' theorem to interpret core electron ionization potentials (1973) (16)
Design of population pharmacokinetic experiments using prior information. (2007) (16)
Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity. (2015) (16)
Model-Based Evaluation of the Impact of Formulation and Food Intake on the Complex Oral Absorption of Mavoglurant in Healthy Subjects (2015) (16)
Mean residence time for drugs subject to reversible metabolism (1987) (16)
Population approaches in drug development (1994) (16)
An Effective Approach for Obtaining Optimal Sampling Windows for Population Pharmacokinetic Experiments (2008) (16)
Drug–drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results (2008) (16)
Dose-dependent pharmacokinetics of cimetidine in the rat. (1987) (15)
Accounting for dropout in xenografted tumour efficacy studies: integrated endpoint analysis, reduced bias and better use of animals (2016) (14)
Optimal Blood Sampling Time Windows for Parameter Estimation Using a Population Approach: Design of a Phase II Clinical Trial (2005) (14)
The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose, Commission of the European Community, Luxembourg (1997) (14)
Modeling and Simulation in Clinical Pharmacology and Dose Finding (2013) (14)
Methodological approaches to the population analysis of toxicity data. (2001) (14)
Bayesian Optimal Designs for Pharmacokinetic Models: Sensitivity to Uncertainty (2007) (14)
Small parasitic parameters and chemical oscillations (1974) (14)
Parabolic structure‐activity relationships: a simple pharmacokinetic model (1982) (13)
Assessment of rate of absorption in bioequivalence studies. (1987) (13)
A Physiologically Based Pharmacokinetic Model for Clobazam and Stiripentol in Adults and Children (2014) (13)
Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates (2017) (13)
Population approaches/sparse data analysis for human variability in kinetics and dynamics. (1996) (13)
Global Sensitivity Analysis of the Rodgers and Rowland Model for Prediction of Tissue: Plasma Partitioning Coefficients: Assessment of the Key Physiological and Physicochemical Factors That Determine Small-Molecule Tissue Distribution (2020) (13)
Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years. (2003) (13)
Mean residence time for drugs subject to enterohepatic cycling (1989) (13)
Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data (2015) (13)
Structural identifiability analysis and reparameterisation (parameter reduction) of a cardiovascular feedback model. (2012) (13)
Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. (2008) (12)
PLASMA CONCENTRATION‐RESPONSE RELATIONSHIP FOR CIMETIDINE INHIBITION OF DRUG METABOLISM IN THE RAT (1985) (12)
Optimisation of sampling windows design for population pharmacokinetic experiments (2008) (12)
Kinetics of drug--drug interactions. (1981) (12)
Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population (2017) (12)
Modelling the genesis and treatment of cancer: the potential role of physiologically based pharmacodynamics. (2010) (12)
Pharmacokinetic and pharmacodynamic aspects of site-specific drug delivery (1989) (12)
Absorption of clonidine from a transdermal therapeutic system when applied to different body sites (1984) (12)
The pharmacokinetics of the enantiomers of flurbiprofen in patients with rheumatoid arthritis. (1991) (12)
Ascorbic acid absorption in patients with systemic sclerosis. (1997) (12)
A Semi-mechanistic Gastric Emptying Model for the Population Pharmacokinetic Analysis of Orally Administered Acetaminophen in Critically Ill Patients (2011) (11)
The binding of flurbiprofen to plasma proteins (1985) (11)
Population pharmacokinetics of the MEK inhibitor selumetinib and its active N‐desmethyl metabolite: data from 10 phase I trials (2018) (11)
Relationship Between Enoxacin and Ciprofloxacin Plasma Concentrations and Theophylline Disposition (1994) (11)
Interaction of mixed micelles formed from glycocholic acid and lecithin with the protein binding of various drugs. (1987) (11)
Incorporating Correlation in Interindividual Variability for the Optimal Design of Multiresponse Pharmacokinetic Experiments (2008) (11)
High-performance liquid chromatographic method for the simultaneous determination of cimetidine and antipyrine in plasma. (1985) (10)
Applied Biopharmaceutics and Pharmacokinetics, Leon Shargel and Andrew B. C. Yu. (1981) (10)
Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas (2017) (10)
Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I–IV drugs (2018) (10)
Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patients. (2017) (10)
Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data (2016) (10)
A Physiologically Based Pharmacokinetic Model for Strontium Exposure in Rat (2013) (10)
General approach to handling nonuniform variance in assay calibration. (1984) (9)
Propagation of Population Pharmacokinetic Information Using a Bayesian Approach: Comparison with Meta-Analysis (2005) (9)
Sample size/power calculations for repeated ordinal measurements in population pharmacodynamic experiments (2010) (9)
Pharmacokinetics of imipenem and cilastatin after their simultaneous administration to the elderly. (1987) (9)
Electronic structure of diazocyclopentadiene. A study using low and high energy photoelectron spectroscopy and ab initio molecular orbital calculations (1974) (9)
Representation and interpretation of drug displacement interactions. (1978) (9)
Multistability in open chemical reaction systems (1976) (8)
Effect of Norfloxacin on Theophylline Disposition: A Comparison with Other Fluoroquinolones (1995) (8)
STEREOSPECIFIC ASSAY OF IBUPROFEN AND ITS METABOLITES (1986) (8)
An improved HPLC assay for monitoring phenylbutazone and its two major oxidised metabolites in plasma. (1980) (8)
HPLC ANALYSIS OF SULPHASALAZINE AND ITS METABOLITES (1980) (8)
Bioavailability of drugs with long elimination half-lives (2004) (8)
Lack of interaction between methotrexate and penicillins. (1999) (8)
Kinetics of drug displacement interactions (1981) (8)
Model‐Based Drug–Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy (2021) (8)
Population pharmacokinetics of cyclosporine: influence of covariables and assessment of cyclosporine absorption in kidney, lung, heart and heart + lung transplanted patients. (1998) (8)
Amiodarone kinetics after single i.v. bolus and multiple dosing in healthy volunteers (2004) (8)
Integration of advanced methods and models to study drug absorption and related processes: An UNGAP perspective. (2021) (7)
Population pharmacokinetics of tiagabine in epileptic patients on monotherapy. (2000) (7)
Analytical Expressions for Combining Population Pharmacokinetic Parameters from Different Studies (2008) (7)
The kinetics of flurbiprofen in synovial fluid (1991) (7)
Sample‐size calculations for multi‐group comparison in population pharmacokinetic experiments (2010) (7)
A note on the use of salicylate saliva concentration in clinical pharmacokinetic studies (1989) (7)
The Influence of Normalization Weight in Population Pharmacokinetic Covariate Models (2018) (7)
Conformational Studies of the Benzophenone and Thiobenzophenone Radical Anions (1972) (7)
Sample Size Calculations for Population Pharmacodynamic Experiments Involving Repeated Dichotomous Observations (2007) (7)
The influence of body weight on the pharmacokinetics of mefloquine. (2002) (7)
Pharmacodynamics of controlled release verapamil in patients with hypertension: an analysis using spline functions (2004) (6)
Design and analysis of protein binding experiments. (1989) (6)
Population pharmacokinetic/pharmacodynamic models for duloxetine in the treatment of diabetic peripheral neuropathic pain (2013) (6)
Time-Dependent Disposition of β-Naphthoflavone in the Rat (2004) (6)
Sparse data analysis (2011) (6)
Equivalent cores method of computing core electron binding energies (1973) (6)
Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug–drug interaction studies for CYP2C9 (2012) (5)
The pharmacokinetics of perindoprilat in normal volunteers and patients: influence of age and disease state. (2005) (5)
Ionization constants and lipophilicity of 1-arylpiperazines investigated by reversed-phase high-performance liquid chromatography (1985) (5)
A study of the dosage and duration for levobupivacaine infusion by the caudal‐epidural route in infants aged 3‐6 months (2019) (5)
A comment on estimating binding constants at variable protein concentrations (1979) (5)
Statistical methods in laboratory medicine (1999) (5)
Plasma and tonsillar tissue pharmacokinetics of teicoplanin following intramuscular administration to children. (1998) (5)
Problems with demonstrating NSAID concentration-response relationships. (1985) (5)
A chronic dose-ranging kinetic study of salicylate in man [proceedings]. (1977) (5)
Interpretation of CO2 exhalation rate data from demethylation of aminopyrine and its metabolite monomethylaminoantipyrine. (1982) (5)
Use of in vitro dissolution data to predict plasma drug profiles. (1977) (5)
Theoretical study of the structure of some trigonal radicals (1974) (5)
Editorial: Pharmacokinetic and pharmacodynamic modelling in drug development (1999) (5)
Pharmacokinetics of controlled‐release verapamil in healthy volunteers and patients with hypertension or angina (2002) (5)
Propagation of Population PK and PD Information Using a Bayesian Approach: Dealing with Non-Exchangeability (2006) (4)
Dose individualisation in oncology using chemotherapy‐induced neutropenia: Example of docetaxel in non‐small cell lung cancer patients (2020) (4)
Design of Population Pharmacokinetic Studies: Sample size Determination (2004) (4)
A semi-mechanistic gastric emptying pharmacokinetic model for (13)C-octanoic acid: an evaluation using simulation. (2012) (4)
Precision criteria to derive sample size when designing pediatric pharmacokinetic studies: Which measure of variability should be used? (2014) (4)
A comparison of the relative sensitivities of factor VII and prothrombin time measurements in detecting drug interactions with warfarin (2004) (4)
Metabolism of theophylline and its inhibition by fluoroquinolones in rat hepatic microsomes. (1995) (4)
Lack of interaction between flucloxacillin and methotrexate in pa tien t s with rheumatoid arthritis (1996) (4)
A pharmacokinetic/pharmacodynamic model for a platelet activating factor antagonist based on data arising from Phase I studies (2005) (4)
Computer-assisted learning lessons in drug disposition and pharmacokinetics. (1988) (4)
Population pharmacokinetics of halofantrine in healthy volunteers and patients with symptomatic falciparum malaria (2012) (3)
High-performance liquid chromatographic determination of beta-naphthoflavone in biological fluids. (1987) (3)
Optimal Experimental Design for Precise Estimation of the Parameters of the Axial Dispersion Model of Hepatic Elimination (1998) (3)
Establishment and validation of microsampling techniques in wild rodents for ecotoxicological research (2018) (3)
Lack of interaction between flucloxacillin and methotrexate in patients with rheumatoid arthritis. (1996) (3)
STRUCTURAL IDENTIFIABILITY OF PARALLEL PHARMACOKINETIC EXPERIMENTS AS CONSTRAINED SYSTEMS (2006) (3)
Structural identifiability analysis of pharmacokinetic models using DAISY: semi-mechanistic gastric emptying models for 13C-octanoic acid (2011) (3)
Choosing an optimal input for an intravenous glucose tolerance test to aid parameter identification (2017) (3)
Population pharmacokinetics of rufloxacin in patients with acute exacerbations of chronic bronchitis (1997) (2)
Evaluation of area under the concentration curve adjusted by the terminal‐phase as a metric to reduce the impact of variability in bioequivalence testing (2021) (2)
On the effect of a small parameter and the possibility of limit cycle behaviour in a negatively inductive control system. (1975) (2)
Handling Missing Data in a Duloxetine Population Pharmacokinetic/Pharmacodynamic Model – Imputation Methods and Selection Models (2014) (2)
Impact of tumour size measurement inter-operator variability on model-based drug effect evaluation (2020) (2)
Prediction of serum tobramycin in patients with NONMEM and simulated annealing. (2003) (2)
Mathematical Modelling of Chronic Drug Infusion for Toxicity Assessment. (2013) (2)
Optimal design of a population pharmacodynamic experiment (2000) (2)
Pharmacodynamic modelling of resistance to epidermal growth factor receptor inhibition in brain metastasis mouse models (2018) (2)
Population Pharmacokinetic Analysis of Ropivacaine and Its Metabolite 2′,6′-Pipecoloxylidide From Pooled Data in Neonates, Infants, and Children (2012) (2)
Ratifying the dosage and duration of levo‐bupivacaine infusion by the caudal‐epidural route in infants aged three to six months (2018) (2)
Application of a linear recirculation model to drug targeting (1991) (2)
Comment on ’’Oscillations in chemical systems. XII’’ (1976) (2)
Time-dependent disposition of beta-naphthoflavone in the rat. (1993) (2)
Computer lung modelling to predict inhaled particle deposition: a comparison of predicted and clinical data (1999) (1)
Salicylate-NSAID interactions. (1984) (1)
Designing More Efficient Preclinical Experiments: A Simulation Study in Chemotherapy-Induced Myelosupression (2015) (1)
COST B15: modelling in drug development (2001) (1)
Whole body physiologically based modelling of β‐blockers in the rat: events in tissues and plasma following an i.v. bolus dose (2018) (1)
Population pharmacokinetics : a Trojan horse? (1992) (1)
A “middle‐out approach” for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) models (2023) (1)
Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data (2015) (1)
Model-based Integration for Clinical Trial Simulation and Design: A Phase ll Case Study for Naratriptan (2003) (1)
Investigation of simplified physiologically‐based pharmacokinetic models in rat and human (2023) (1)
Intravitreal Pharmacokinetic Study of the Antiangiogenic Glycoprotein Opticin (2020) (1)
PHARMACOKINETICS OF SALICYLATE AFTER CHRONIC DOSING IN MAN (1978) (1)
Absorption and Excretion of Clonidine Following Application of Catapres-TTS to Different Skin Sites (1985) (1)
A whole body physiologically based pharmacokinetic model for the distribution of barbiturates in rats (1996) (1)
A Pharmacokinetic Model for Tenidap in Normal Volunteers and Rheumatoid Arthritis Patients (1999) (1)
Design of population pharmacokinetic experiments using prior information (2007) (1)
ACCOUNTING FOR NONUNIFORM VARIANCE IN ASSAY CALIBRATION (1982) (1)
Critical Analysis and Communication: An Alternative to the Research Project (2014) (1)
Erratum to: Quantitative Structure-Pharmacokinetics Relationships: I. Development of Whole-Body Physiologically Based Model to Characterize Changes in Pharmacokinetics Across a Homologous Series of Barbiturates in the Rat (1998) (1)
Predictive Models for Target Response During Penetration (2014) (1)
Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 1: methotrexate (2014) (0)
Qualitative model for the prediction of high/low human oral bioavailability from animal bioavailability data employing ROC analysis (2013) (0)
Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate (2014) (0)
An Exploratory Analysis to Determine the Feasibility of Raltegravir Population Pharmacokinetics in HIV-Infected Infected Patients and Healthy Volunteers (2009) (0)
Physiologically based pharmacokinetc modeling of a homologous series of barbiturates in the rat. II. A Sensitivity analysis of the model. (1997) (0)
Population Pharmacokinetic Modeling of Acetaminophen (APAP), A Surrogate for Gastric Emptying, in Critically Ill Patients Tolerant And Intolerant To Enteral Nutrition (2010) (0)
What do we mean by identiability in mixed effects models (2016) (0)
The role of modelling and simulation in clinical pharmacology (2013) (0)
Qualitative prediction of human oral bioavailability from animal oral bioavailability data employing ROC analysis (2013) (0)
Design and Analysis of Population Pharmacokinetic Experiments in Children – Famciclovir Example (2009) (0)
Global Sensitivity Analysis of the Rodgers and Rowland Model for Prediction of Tissue: Plasma Partitioning Coefficients: Assessment of the Key Physiological and Physicochemical Factors That Determine Small-Molecule Tissue Distribution (2020) (0)
The use of pharmacokinetic models in the development and evaluation of site-specific drug delivery systems (1990) (0)
A General Method for Optimal Design of Univariate and Multivariate Population Pharmacokinetic Experiments (2006) (0)
Translating Human Effective Jejunal Intestinal Permeability to Surface-Dependent Intrinsic Permeability: a Pragmatic Method for a More Mechanistic Prediction of Regional Oral Drug Absorption (2015) (0)
Human drug kinetics: A course of simulated experiments: by L. Saunders, D. Ingram and S. H. D. Jackson, IRL Press, 1989. £100.00 (book and software) (261 pages) ISBN 0 19 96 3039 9 (1990) (0)
Modelling the change in lopinavir apparent oral clearance over time following cessation of lopinavir/ritonavir: data from the TAIL study (2008) (0)
DESIGN AND ANALYSIS OF THE AMINOPYRINE BREATH TEST (1985) (0)
Study of the phamacokinetic profile of anti-epileptic drugs in an adult Omani epileptic population using NONMEM. (2002) (0)
Comparison of in vivo and in silico methods to predict tissue:plasma partition coefficients in rat (2009) (0)
Predicting the Higher Bioavailability Observed for Oxybutynin ’ s OROS Formulation Compared to the Immediate-Release ( IR ) Tablet Using a Novel Simplified Absorption PBPK Model (2015) (0)
Development of a Novel Simplified PBPK Absorption Model to Explain the Higher Relative Bioavailability of the OROS® Formulation of Oxybutynin (2016) (0)
Development and evaluation of a classification tool for the qualitative prediction of oral bioavailability from animal data (2013) (0)
What do we mean by identifiability in mixed effects models? (2015) (0)
Can BDDCS Class be used to explain differences in the prediction of human oral bioavailability from animal data using a threshold-based model? (2013) (0)
Population pharmacokinetics oftobramycin (1989) (0)
Empirical and Semi-Mechanistic Modelling of Double-Peaked Pharmacokinetic Profile Phenomenon Due to Gastric Emptying (2014) (0)
The analysis of categorical/count data (1999) (0)
"Population modelling". In: Variability in Human Drug Response. Proceedings of the Esteve Foundation Symposium VIII. (1999) (0)
Focal rheumatoid-like prostatic granulomas (1984) (0)
The population pharmacokinetics of lapdap (2002) (0)
The design and analysis of parallel experiments to produce structurally identifiable models (2013) (0)
A mechanistically based model for the relationship between the tissue distribution parameters and the lipophilicity of a homologous series of barbiturates in rats (1999) (0)
Population Pharmacokinetics of Ritonavir-Boosted Boosted Atazanavir in HIV-Infected Infected and Healthy Individuals (2009) (0)
Olivares Morales et al Peff SA Supplementary (2015) (0)
Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations (2015) (0)
What do we mean by identi ability in mixed e ects models ? (2018) (0)
Development of a novel method for updating the predicted partition coefficient values generated by an existing in silico prediction method (2010) (0)
On representation and interpretation of drug displacement interactions [proceedings]. (1977) (0)
Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions (2015) (0)
Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach (2014) (0)
924 – SALICYLATE BINDING AND THE EFFECT OF BINDING ON THE RATE OF ASPIRIN HYDROLYSIS IN VITRO (1978) (0)
Sample Size Calculation for Pharmacokinetic Studies (2002) (0)
Investigations into thepotential effects ofmultiple doseketorolac on thepharmacokinetics andpharmacodynamics ofracemic (1990) (0)
Optimal Design for Drug-Drug Interaction Study Using PopDes - Application to SX and MDZ” and “PopDes - An Optimal Experimental Design Program for Individual and Population Uniresponse and Multiresponse PKPD models (2007) (0)
Computer Assisted Design of Phase II(b) Oral Dose Ranging Trial for Naratriptan - Results of a Pilot Study. Scientific Conference "Pharmacokinetics - UK", Manchester, UK. November 4-6, 1998 (1998) (0)
Model-Based Evaluation of the Impact of Formulation and Food Intake on the Complex Oral Absorption of Mavoglurant in Healthy Subjects (2014) (0)
DMD # 36103 1 Critique of the two-fold measure of prediction success for ratios : application for the assessment of drug-drug interactions (2010) (0)
Erratum: Optimal Design of a Population Pharmacodynamic Experiment for Ivabradine (2004) (0)
The Use of ROC Analysis for the Qualitative Prediction of Human Oral Bioavailability from Animal Data (2013) (0)
Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed. (2021) (0)
Critical Analysis and Communication: an alternative to the final year project (2014) (0)
Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics (2015) (0)
ON REPRESENTATION AND INTERPRETATION OF DRUG DISPLACEMENT INTERACTIONS (1977) (0)
Development and Application of Regional Intestinal Permeability Surface Area Scaling Factors for the Prediction of Oral Drug Absorption in the Distal GI Tract (2014) (0)
Handling Missing Data in a Duloxetine Population Pharmacokinetic/Pharmacodynamic Model – Imputation Methods and Selection Models (2014) (0)
A physiologically-based pharmacokinetic model for the distribution of barbiturates in rats. AAPS Tenth Anniversary Meeting, 27-31 October 1996, Seattle, Washington (1996) (0)
Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug–drug interaction studies for CYP2C9 (2012) (0)
2020 Reviewer Thanks (2021) (0)
Towards a Population Pharmacokinetic/Pharmacodynamic Model of Anti-VEGF Therapy in Patients with Age-Related Macular Degeneration (2023) (0)
Correlation of MICs of ketoconazole (KTZ) and itraconazole (ITZ) for C. albicans with clinical outcome of treatment of oropharyngeal candidiasis in HIV patients with a population pharmacokinetic analysis (1998) (0)
Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I–IV drugs (2018) (0)
II C11 Population pharmacokinetics of anti-epileptic drugs in adult Omani epileptic patients.ecc (2002) (0)
Variability associated with PBPK prediction and extrapolation to man (2005) (0)
A Physiologically Based Pharmacokinetic Model for Strontium Exposure in Rat (2013) (0)
A Physiologically Based Pharmacokinetic Model for Clobazam and Stiripentol in Adults and Children (2014) (0)
Welcome and session 1 : Mechanistic Modelling of Drug Absorption (2009) (0)
An in silico physiologically-based pharmacokinetic (PBPK) study of the impact of the drug release rate on oral absorption, gut wall metabolism and relative bioavailability (2014) (0)
Mixed effects modelling of toxicokinetic data (2002) (0)
Simultaneous fitting of the Minimal Model to IVGTT & Glucose Clamp Data (1999) (0)
Sample Size Calculation based on Confidence Interval for Population Pharmacokinetic Studies (2003) (0)
Founding figures of pharmacokinetics: tribute to Malcolm Rowland. (2010) (0)
ELECTRONIC STRUCTURE OF DIAZOCYCLOPENTADIENE, A STUDY USING LOW AND HIGH ENERGY PHOTOELECTRON SPECTROSCOPY AND AB INITIO MOLECULAR ORBITAL CALCULATIONS (1974) (0)
A reduced physiologically-based pharmacokinetic (PBPK) model for the prediction of regional gastrointestinal (GI) drug absorption (2015) (0)
CORRIGENDUM: Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas (2017) (0)
Evaluation of a rate-adjusted area under the curve method to reduce the impact of variability in bioequivalence testing (2020) (0)
Editorial (1999) (0)
Computer-assisted clinical trial simulation: a phase II case study with naraptriptan (2001) (0)

This paper list is powered by the following services:

Other Resources About Leon Aarons

en.wikipedia.org

What Schools Are Affiliated With Leon Aarons?

Leon Aarons is affiliated with the following schools:

University of Manchester